An open label, randomized, single-dose, two-treatment, two-period, cross-over pilot bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
This research is looking at two versions of a medicine called pyridostigmine bromide. One is a new tablet from Greece, and the other is an existing tablet from Germany, known as Mestinon® retard. Both are 180mg prolonged-release tablets. The main aim is to see if the new Greek medicine works in the body in the same way as the German one. This is called a 'bioequivalence study'. To do this, healthy male and female volunteers will take both medicines on different occasions, under strict conditions (like not eating beforehand). The study helps to ensure that if the new medicine is approved, it will be just as effective and safe for people who have myasthenia gravis, a condition that causes muscle weakness.
At a glance
What is this study about?
Imagine you have a jigsaw puzzle, and you need a specific piece to complete it. This study is a bit like checking if a new puzzle piece (a new version of a medicine) fits in exactly the same way as an old, familiar piece (an existing medicine).
The medicine being tested is called pyridostigmine bromide. It's used to help people with a condition called myasthenia gravis. This condition makes muscles weak and tired. Pyridostigmine helps their muscles work better. There's an established version of this medicine, Mestinon® retard, and a new version made by a different company. This study wants to confirm that the new version acts in the body just like the established one.
This kind of study is called a 'bioequivalence' study. It means researchers want to see if two different versions of a medicine deliver the same amount of the drug to the bloodstream at the same speed. If they do, it means they are 'bioequivalent' and should have the same effects. This is a crucial step to ensure that any new medicine made available to patients is just as reliable and effective as the ones they already use.
Key takeaways
- This study compares two versions of a muscle-strengthening medicine.
- It's for healthy volunteers, not people with a medical condition.
- The goal is to see if a new medicine works the same way as an existing one.
- Participants will take both medicines and have blood tests.
- It's an early-stage study, focused on how the medicine acts in the body.
Who may be eligible?
This study is looking for healthy men and women aged 18 years and older. There isn't an upper age limit, meaning older adults are welcome to participate as long as they are healthy.
Since this is an early-stage study, it focuses on healthy volunteers rather than people with existing medical conditions. This helps researchers understand how the medicine behaves in the body without other health problems potentially complicating the results.
More specific health checks will be done by the study team to make sure it's safe for you to take part. For example, they'll check your general health, blood, and other factors to ensure you meet all the safety requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy?
- Are you able to follow study instructions carefully?
- Are you comfortable with having regular blood samples taken?
What does participation involve?
If you decide to take part, you'll visit the study clinic multiple times. You'll take each of the two different pyridostigmine medicines on separate occasions. This is done in a 'cross-over' way, meaning you'll receive one medicine first, then after a break, you'll receive the other.
You'll need to fast (not eat) before taking the medicine. After taking each medicine, the study team will take regular blood samples over several hours to see how the medicine is absorbed and leaves your body. You'll be closely monitored by healthcare professionals throughout these visits. The total duration of your involvement, including all visits and follow-up, will be explained in detail.
Potential risks and benefits
Locations (1)
- —UnverifiedCzechia
Common questions
What is pyridostigmine bromide used for?
It's a medicine used to treat myasthenia gravis, a condition that causes muscle weakness.
What does 'bioequivalence' mean?
It means the study is checking if two different versions of the same medicine work in the body in the exact same way, delivering the same amount of drug at the same speed.
Do I need to have myasthenia gravis to join?
No, this particular study is for healthy volunteers only.
Will I take both medicines?
Yes, you will take each of the two different medicines on separate occasions during the study.
Why is this study important?
It helps make sure that if a new version of pyridostigmine is made available, it will be just as effective and safe as existing treatments for patients with myasthenia gravis.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.